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Abstract
Genotoxicity is commonly evaluated during the chemical safety assessment together with other toxicological endpoints.
The micronucleus test is always included in many genotoxic test guidelines for long time in many classes of chemicals,
e.g., pharmaceutical chemicals, agricultural chemicals, food additives. Although the trend of the safety assessment
of chemicals faces to animal welfare and in vitro systems are more welcome than the in vivo systems, the in vivo
test systems are paid more attention in the field of genotoxicity because of its weight of evidence. In this review,
I will summarize the following points: 1) historical consideration of the test development, 2) characteristics of the
test including advantages and limitations, 3) new approaches considering to the animal welfare.
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Background
The micronucleus was recognized in the end of the 19th
century when Howell and Jolly found small inclusions in
the blood taken from cats and rats. The small inclusions,
called Howell-Jolly body, are also observed in the erythro-
cytes of peripheral blood from severe anemia patients.
These are the first description of the micronucleus itself.
In this review, I introduce historical aspects on the use of
the micronucleus test as one of in vivo mammalian geno-
toxicity tests.
Historical consideration of the micronucleus test
The micronucleus was recognized in the end of the 19th
century when Howell and Jolly found small inclusions in
the blood taken from cats and rats. The small inclusions,
called Howell-Jolly body, are also observed in the eryth-
rocytes of peripheral blood from severe anemia patients.
These are the first description of the micronucleus itself.
In 1959, Evans et al. [1] reported that gamma-rays induced
micronuclei in root tips of kidney beans, and tried to evalu-
ate the chromosomal aberration quantitatively. This was the
first report to evaluate chromosomal aberration by the fre-
quency of cells harboring micronucleus among normal cells
and they estimated that about 60 % of the chromosomal
fragments contributed to micronucleus formation.
In 1970, Boller and Schmid [2] developed a test method
to evaluate the frequency of micronucleated erythrocytes
among normal erythrocytes, which lack their own nuclei
during hematopoiesis, using bone marrow and peripheral
blood cells of Chinese Hamster treated with a strong al-
kylating agent, trenimon. In the paper, they named this
method as "Mikrokern-Test (micronucleus test)". Up to
the mid 1970's Schmid [3] and Heddle's [4] group built up
the basics of the micronucleus test.
In 1976, Countryman and Heddle [5] reported a
method using human cultured lymphocytes. Modifica-
tions have been introduced by Fenech and Moley [6]
using cytocharasin B and now the method is widely used
for human monitoring.
In 1979, Cole et al. [7] and King and Wild [8] observed
induction of micronucleus which appears in the fetal
mouse liver and peripheral blood cells at the very late stage
of gestation whose mothers were treated intraperitoneally
with a clastogenic chemical. Some chemicals get metabo-
lized in the liver and become their active form. When the
active forms are unstable and diminish before reaching the
bone marrow, the clastogenicity of these chemicals will not
be detected by the usual method. Using fetal micronucleus
method, however, the unstable active metabolites (e.g.,
dialkyl-nitrosamine) could be detected [9].
In 1980, MacGregor et al. [10] reported a method to
detect micronucleus in mouse peripheral erythrocytes.
Micronucleus is hardly seen in the peripheral blood of
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rats and humans because erythrocytes including micro-
nuclei are captured and destroyed by the spleen rapidly
and effectively. In mice, however, micronucleated eryth-
rocytes exist just the same as normal cells in the periph-
eral blood. The assay using bone marrow evaluates an
acute effect of chemicals but the method using mouse
peripheral blood erythrocytes can evaluate a chronic ef-
fect of the test chemical by analyzing of mature erythro-
cytes which harboring micronuclei up to their life span.
In 1981 and 1983, Lähdetie et al. [11] and Tates et al.
[12] reported a method using male germ cells. The reports
suggested the possibility of using the micronucleus test to
detect potential of heritable adverse effects of chemicals.
In 1983, the micronucleus committee of US-EPA Gene
Tox Program reported an overall summary including
database of evaluated micronucleus test results of chemi-
cals assayed up to that time [13]. An international collab-
orating program to evaluate short term studies has also
started by International Program on Chemical Safety
(IPCS) this year. Carcinogens and non-carcinogens were
evaluated by several in vivo test systems and the micronu-
cleus test obtained the best score to estimate the carcino-
genic potential of chemicals among assays studied [14].
In 1983, Hayashi et al. [15] and MacGregor et al. [16] in-
troduced the fluorescence staining method. Hayashi et al. re-
ported a fluorescent staining method using acridine orange
to identify specifically micronuclei by yellowish green fluor-
escence emitted from DNA concomitantly to identify imma-
ture erythrocytes by red fluorescence emitted from RNA.
MacGregor et al. reported an alternative fluorescent staining
method to identify micronuclei and immature erythrocytes
using Hoechst 33258 and pyronin Y. These DNA and RNA
specific methods contributed to increase the accuracy of
scoring micronucleated immature erythrocytes.
From early 1980's, some countries as well as international
organizations started to make their own test guidelines for
evaluating safety assessment of chemicals. The micronucleus
test is included in the genotoxicity test battery. Under the
circumstance, from 1984 up to now, the Collaborative Study
Group for the Micronucleus Test under the Mammalian
Mutagenicity Study Group, which is a sub-organization of
Environmental Mutagen Society of Japan (CSGMT/JEMS-
MMS), started to study on various factors which could affect
the test results. Up to date, the followings have been studied
and reported: the sex-related difference [17], the strain dif-
ference [18], the difference between intraperitoneal injection
and oral gavage application [19], the effect of the number of
treatments [20], the micronucleus test with peripheral blood
using acridine orange supravital staining method [21], the
aging of mice [22, 23], the performance of the test on che-
micals categorized in IARC groups 1, 2a and 2b [24], the mi-
cronucleus using rat peripheral blood [25], the 28-days
repeat treatment micronucleus test [26], and the test tar-
geted other than erythropoietic tissues [27, 28]. These
outcomes of the collaborative trials have given a lot of im-
pacts and valuable contributions to standardize the test
protocol and accordingly to the test guidelines, e.g., ICH
S2(R1) and OECD TG 474 [29, 30].
Micronucleus test can also detect spindle poisons [31],
and in that case, the micronuclei are larger than usual in size
[32, 33]. In 1988, the kinetochore specific staining using
antibody was introduced to detect chemicals which cause
dis-function of mitotic apparatus [34]. Hayashi et al.
reported the method to isolate micronuclei from peripheral
blood and to distinguish between micronuclei with and
without centromere [35].
As early as 1986, the automation for the analysis of
micronucleated erythrocytes has been approached by flow
cytometry [36–39] and also by image analyzer systems
[40, 41]. Using the flow cytometry, the dose-response rela-
tion was studied with ionizing radiation until very low
dose level [42]. These kind studies can be practically be-
cause the flow cytometer can analyze a large number of
cells in a short period, accordingly the statistical power to
detect micronucleus induction would increase.
In 1990, the committee of US-EPA Gene Tox Program
published a revised edition of the 1983's report [13, 43]. This
revision includes new data and ideas for a new protocol.
From 1992, the movement of the international
harmonization of genotoxicity test systems from the meth-
odological view point. In December 1992, as the pre-
meeting for the International Workshop on Standardization
of Genotoxicity Test Procedures (IWGT), organizers and
chairpersons met together in Tokyo, and extracted question-
able points from each assay which should be discussed at
the workshop. In 1993, the international workshop was
taken place for two days at Melbourne attached to the 6th
International Conference on Environmental Mutagens and
selected points were discussed and reported [44]. After that
time, the IWGT, as a rule, took place as a satellite meeting
of each ICEM [45, 46].
Recently, the OECD TG 474, Mammalian Erythrocyte
Micronucleus Test was updated [30]. For any purposes
the micronucleus test data should be reliable and accurate.
Thorough understandings on the mechanism of micronu-
cleus formation, and the characteristics and limitations of
the method, the experiment should be carefully done by
the experienced and skillful persons, and thereby the satis-
factory and reliable outcomes will be obtained.
Characteristics of the test including advantages
and limitations
Micronucleus test does not take a direct observation of
chromosomes in the cell metaphase. However, the micro-
nucleus test is not suggested to be a simply alternative
method for metaphase analysis or the results of the assay
have less value compared to those of chromosomal aber-
ration test. The author believes the micronucleus test as a
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related to but an independent method from chromosomal
aberration test with its own characteristics. The character-
istics of the micronucleus test compared to the metaphase
analysis: <1 > any dividing cell population can be used re-
gardless of its karyotype (Fig. 1), <2 > accurate data can be
obtained because its endpoint is simple and easy to iden-
tify, <3 > response can be detected for longer duration,
<4 > spindle poisons can also be detected, <5 > the back-
ground frequencies of micronucleated cells are usually
stable, <6 > an additional treatment of chemicals other
than test articles, e.g., colcemid or BrdU, is not required,
but <7 > types of chromosomal aberration cannot be clas-
sified by micronuclei and <8 > possibility of appearance of
pseudo-micronucleus under some circumstances.
All the issues are important advantages as well as limita-
tion of the micronucleus test. Among these, “<2 > accurate
data can be obtained because its endpoint is simple and
easy to identify” to be discussed here. In the micronu-
cleated erythrocyte, the micronucleus is only DNA compo-
nent in the cell because the main nucleus of the cell is
expelled during the erythropoiesis of mammals and the
structure is simple. Such feature is suitable for identifica-
tion of evidence of chromosomal aberration by machines
automatically, e.g., image analysis or flow cytometry. A
contemporary flow micronucleus test developed by
Dertinger and his group is most widely used among auto-
mating scoring systems. Their system includes gating for
young erythrocyte by immunostaining of erythrocyte mem-
brane and also gating the amount of DNA. Usually, they
analyze 20000 young erythrocytes but a million cells can
be analyzed without any difficulty. This means the statis-
tical power can be increased easily when the cell is consid-
ered to be a unit of analysis. The current revised OECD
TG 474 proposed 4000 young erythrocytes should be ana-
lyzed, which is twice the number of cells stated in the
former guideline. It is time consuming and tedious work to
analyze 4000 young erythrocytes in the case of the ordinal
microscopic analysis, but the flow cytometer can do that
easily. The reproducibility of the outcomes between labora-
tories looks good and the system considered to be well
validated.
Only the problem, however, is the interpretation of
data that shows very slight increase compared to the
control under some experimental conditions when the
statistical power increased. It is not only the case of the
micronucleus test but the other test systems with in-
crease statistical power. For hazard identification it
might be powerful but it is difficult to interpret in the
case of the risk assessment. This is a difficult problem to
be solved in the regulatory science [47, 48].
Fig. 1 Comparison of the appearance between karyotypes and micronucleated cells. Karyotype and micronucleus (arrow) of fresh water fish
(Carassius sp.) (a and d), mouse (b and e), and Chinese hamster (c and f). The micronuclei are simple structure independently from complexity of
karyotype of each species
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New approaches considering to the animal
welfare
Considering animal welfare, this in vivo test should ap-
proach to follow the 3Rs (Replacement, Reduction, and
Refinement). One other hand, each test is required to
show the high sensitivity, which means increment of test
animals. To resolve such contradictive requirement, we
have tried several approaches, i.e., 1) omission of the
concurrent positive control group from the test protocol,
2) combination of two or more test systems, e.g., the mi-
cronucleus test and the comet assay, and 3) incorpor-
ation of the micronucleus test into other toxicological
studies, e.g., repeat dose study.
1) The micronucleus test usually performed routinely to
evaluate in vivo of chemicals. In such cases, the
historical positive control can assure the performance
of the test, and concurrent positive control group is
not necessary to include in all tests. It is, however,
recommended to use the positive control slides, which
prepared separately, to certify the proper staining and
observation. ICH S2(R1) guideline and OECD TG 474
accepted the omission of the concurrent positive
control [29, 30, 49]. This approach reduces the
number of test animals from each study.
2) Up to recently, the in vivo genotoxicity tests have
been run standalone as other animal toxicological
studies. To approach the 3Rs concept, two or more
assay systems are combined as the multiple endpoint
assays. The difficulty was how to overcome the
different optimal treatment regime for each test,
especially sampling time after the last treatment.
Originally, this point was overcome by using
peripheral blood as target cells of the micronucleus
test and we do not have to kill animals at each
sampling time, which adjust the protocol to the
other assay system. For example, we can use
transgenic animal model to detect gene mutations
together with the micronucleus evaluation for
chromosomal aberration. Recently, the combination
of the micronucleus test and the comet assay is
being used most frequently to detect together
chromosomal aberration and DNA damage by 3
treatment protocol. Animals are killed at short
period (e.g., 3 h) after the third treatment that fit
optimal for the both assays [49].
3) The guideline of ICH S2(R1) recommends to
integrate genotoxic endpoints, e.g., micronucleus
formation, into general repeat dose toxicological
study. Theoretically, we can take peripheral blood
sample at any time during the study, and bone
marrow cells at the termination of the study. Of
course, there are several restrictions to perform the
toxicological study completely, but we can use
animals of the satellite group, if any. The most
important point of the integration study is the dose
levels. Generally, the dose levels of the repeat dose
study are lower than those of the standalone or
combination micronucleus test. The ICH guideline
suggests when mammalian cell assay gives positive
or omits mammalian assay, several factors should be
evaluated to determine whether the top dose is high
enough for the appropriate genotoxicity evaluation.
If one or more criteria listed below are considered to
be sufficient to evaluate in vivo:
i. Maximum Feasible Dose (MFD) based on
physico-chemical properties of the drug in the
vehicle is similar to that achievable with acute
administration.
ii. Limit dose of 1000 mg/kg for studies of 14 days
or longer, if this is tolerated.
iii. Maximal possible exposure demonstrated either
by reaching a plateau/saturation in exposure or
by compound accumulation. In contrast,
substantial reduction in exposure to parent drug
with time (e.g., ≥ 50 % reduction from initial
exposure) can disqualify the study (unless a blood
sample taken in the first few days is available). If
this is observed in one sex, generally the sex with
reduced exposure would not be scored at the end
of the study, unless there is enhanced exposure to
a metabolite of interest.
iv. Top dose is ≥ 50 % of the top dose that would be
used for acute administration, i.e., close to the
minimum lethal dose, if such acute data are
available for other reasons. (The top dose for
acute administration micronucleus tests is
currently described in OECD guidance as the
dose above which lethality would be expected;
similar guidance is given (e.g., Hartmann et al.,
2003) for other in vivo assays.)
Selection of a top dose based on only an exposure
margin (multiple over clinical exposure) without toxicity
is not considered to be sufficient justification. These ap-
proaches are appropriate for reduction of test animals
and we should consider any of these approaches for the
good practice of animal welfare.
Conclusion
The in vivo rodent micronucleus assay has limitations as
other genotoxicity assays, namely no one assay can
detect all genotoxic chemicals with different modes of
actions. It is, however, the micronucleus assay has been
most widely used as an in vivo assay as the most reliable
assay to assess the induction of chromosomal aberra-
tions, which is one of two major endpoints of mutage-
nicity, for not only hazard identification but also risk
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assessment. There is also no doubt the assay has more
weight in the course of risk assessment than other assays
including in vitro mammalian chromosomal aberrations
assay although it has shortcomings in the view point of
animal welfare. At the present time, still animal studies
are important for safety assessment of chemicals and the
attempts mentioned in this review should be appreciated
to reduce experimental animals. We have to make bal-
ance also in the field of safety assessment between
weight of evidence and animal welfare.
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